安裝中文字典英文字典辭典工具!
安裝中文字典英文字典辭典工具!
|
- Ibrutinib Resistance Mechanisms and Treatment Strategies for . . .
BTK is a central contributor to B-cell lymphoma pathogenesis, as it is significantly more active (increased phosphorylation) in B-cell lymphomas than in normal B-cells Additionally, BTK plays a fundamental role in modulating chemokine and integrin signaling (CXCR4), thereby regulating B-cell trafficking and tissue homing [ 7 ]
- Ibrutinib improves diffuse large B-cell lymphoma survival
NCI researchers have found that adding the targeted therapy ibrutinib (Imbruvica) to standard chemotherapy can improve how long some younger people with a specific form of diffuse large B-cell lymphoma live The new findings come from a new analysis of a previously conducted phase 3 clinical trial called Phoenix
- Imbruvica (Ibrutinib) | Lymphoma News Today
A total of 56 patients with various types of B-cell NHL were enrolled in the study The results showed that Imbruvica was well-tolerated across various types of B-cell NHL The FDA approved Imbruvica in 2013 for the treatment of patients with MCL based on the results of an open-label Phase 2 trial (NCT01236391) During the trial, 111 patients
- IMBRUVICA® (ibrutinib) | Official Patient Website
The most common side effects of IMBRUVICA® in adults with B-cell malignancies (CLL SLL and WM) include low platelet count; diarrhea; tiredness; muscle, bone, and joint pain; low white blood cell count; rash; low red blood cell count (anemia); bruising; and nausea
- Ibrutinib improves survival for younger people with diffuse . . .
“This new analysis provides a compelling rationale for doctors to consider adding ibrutinib to standard chemotherapy for the initial treatment of younger patients with non-GCB DLBCL,” said Wyndham H Wilson, M D , Ph D , senior investigator in the Lymphoid Malignancies Branch and a co-author of the study DLBCL is the most common type of
- Efficacy and safety of ibrutinib in diffuse large B-cell . . .
The pooled OR and CR were 64 2 % and 56 9 % in non-germinal center B-cell-like (non-GCB) DLBCL and 68 3 % and 36 0 % in relapsed refractory central nervous system lymphoma (CNSL), respectively The pooled median progression-free and overall survival were 4 54 months and 11 5 months, respectively 70 7 % and 52 6 % patients experienced ≥ grade
- Official Healthcare Professional Website | IMBRUVICA . . .
Cytopenias: In 645 patients with B-cell malignancies who received IMBRUVICA ® as a single agent, grade 3 or 4 neutropenia occurred in 23% of patients, grade 3 or 4 thrombocytopenia in 8%, and grade 3 or 4 anemia in 2 8%, based on laboratory measurements Monitor complete blood counts monthly
- Ibrutinib in Patients with Relapsed or Refractory Diffuse . . .
Based on gene profiling, DLBCL can be further classified as activated B-cell-like lymphoma (ABC), germinal center B-cell-like lymphoma (GCB) and primary mediastinal B-cell lymphoma Most patients of DLBCL achieve complete remission (CR) after treatment with R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone), which is
|
|
|